Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive Sofosbuvir + Ribavirin in Liver Transplant Recipients with Active HCV Infection
2014-002317-32Phase 2Active
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and ribavirin in hepatitis C virus infection, sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: SVR12. Started Sep 2014; status: active.
02
Drugs
sofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-002317-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002317-32.